Safety of intravitreal Iow-dose reinjections of triamcinolone acetonide

杜磊,邢怡桥,陈长征
DOI: https://doi.org/10.3969/j.issn.1004-4469.2005.04.015
2005-01-01
Abstract:Objective To evaluate the safety of low-dose intravitreal reinjections of triamcinolone acetonide.Design Prospective,noncomparative,interventional study.Participants 31 cases(31 eyes),including cystoid macular edema (16 cases),diabetic macular edema (6 cases),exudative age-related macular degeneration (4 cases),central or branch retinal vein occlusion (3 cases) and noninfectious uveitis (2 cases).Methods Every time 4mg triamcinolone acetonide was injected into the vitreous cavity.Mean interval between the first injection and the second (31 cases) or third injection (9 cases) were 2.9±1.1 months and 4.5±2.5 months,respectively.Visual acuity and intraocular pressures (IOP) were measured after each injection.Mean follow-up period was 8.4±1.6 months.Main Outcome Measures Intraocular pressures,visual acuity.Results Compared with single injection,reinjections of triamcinolone acetonide had no extra complication occurred.After the first,second and third injection,respectively,intraocular pressure remained normal in 23(74.2%),24(77.4%)and 7(77.8%)eyes.Mean IOP had no significant difference among each post-injection in reinjections cases.2 cases (6.5%) caught obvious cataract and needed surgery.Conclusion Intravitreal low-dose reinjections of triamcinolone acetonide is safe and effective during a short-term follow-up.
What problem does this paper attempt to address?